1. R-GDP (Rituximab + Gemcitabine, Dexamethasone, Cisplatin)
- Indication:
- Relapsed or refractory DLBCL and follicular lymphoma
- Often used as salvage therapy or alternative to R-ICE before stem cell transplant
- Eligible Patients:
- Transplant-eligible patients needing a salvage regimen
- Also appropriate for older or frailer patients due to lower toxicity profile
- Pros:
- Less intensive, outpatient-friendly
- Reduced neurotoxicity compared to regimens with vincristine or high-dose cytarabine
- Shorter infusion time and fewer hospital admissions
- Key Toxicities:
- Myelosuppression (neutropenia, thrombocytopenia)
- Nephrotoxicity (from cisplatin)
- Nausea/vomiting (moderate emetogenic risk)
- Fatigue, infections